Authors
Latest:
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered InvestmentMichael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Latest:
Promotional Review Committees Shire Sets the Standard on Achieving High Performing TeamsWhat does it take for internal Promotional Review Committees to function at their best and avoid costly mistakes to the company? A leading industry practitioner offers 15 tips for high performing teams.
Latest:
Paul Hudson: A Mindset for MiraclesWith healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.
Latest:
Strengthen your greatest asset: your voiceThe quality of our voice can say more about us then the words we speak.
Latest:
Outcomes Data: A Critical Insight for Market AccessReal-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Latest:
Outcomes Data: A Critical Insight for Market AccessReal-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Latest:
Industry Growth Slowdown in BrazilThe Brazilian economy is being impacted by internal and external factors, and forecast figures are being quickly revised downwards. Market research released by Brazil’s Central Bank revised average analysts’ projections for economic growth in 2014 down to 0.70% from 0.90% four weeks earlier(1).
Latest:
Find a key to the impossible accountSince sales success starts by reaching the decision-maker, sales representatives must find creative ways to penetrate the barriers that surround the toughest accounts.
Latest:
Field of DreamsCancer makes neurology seem almost simple by comparison. Cancers come in a nearly infinite variety. Yet their mechanisms, scientists now surmise, may reside in the same place-deep inside the cell. DNA, genes, and cellular proteins play key roles in both disease areas.
Latest:
Special DeliveryNew drug delivery mechanisms and devices are an opportunity to build relationship with the ultimate customer: the patient.
Latest:
New Rules for a New AfricaAs growth in the BRICs and other emerging economies begins to stabilize, companies are finally turning their attention to Africa-a hidden trove of potential that is only as good as you make it.
Latest:
Orchestrating ComplianceProduct managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.
Latest:
Feeling No PainLifecycle management and line extensions helped the Percocet franchise generate steady annual growth, rising from $40 million in 1997 sales to $214 million in 2003, despite the fact that it had no patent protection.
